ONCT - Oncternal Therapeutics down 8% despite promising cirmtuzumab results in broad cancer indications

Oncternal Therapeutics (ONCT) announces the presentation of three posters at the AACR Meeting 2021. Poster Title: A Phase 1b Trial of Cirmtuzumab and Paclitaxel in Locally Advanced/Unresectable or Metastatic Her2 Negative Breast CancerOf 15 intent-to-treat patients, eight patients (53%) had a best response of partial response ((PR)) and four patients (27%) had stable disease ((SD)).Of the 14 patients who were evaluable for efficacy, eight patients (57%) had a PR and four patients (29%) had SD.Poster Title: Inhibition of ovarian and endometrial cancer cell proliferation by an anti-ROR1 monoclonal antibodyIn this preclinical study, cirmtuzumab demonstrated single agent activity against these tumor types, and also enhanced the anti-proliferative effects of commonly-used chemotherapies in these cancers.Future studies will further evaluate cirmtuzumab in ovarian and endometrial cancers in vitro and in relevant in vivo models.Poster Title: Selective androgen receptor degraders for the treatment of androgen receptor ((AR))-positive, triple-negative breast cancer ((TNBC))In this preclinical study, SARDs demonstrated anti-tumor activity in a

For further details see:

Oncternal Therapeutics down 8% despite promising cirmtuzumab results in broad cancer indications